These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
598 related articles for article (PubMed ID: 28691390)
1. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues. Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390 [TBL] [Abstract][Full Text] [Related]
2. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791 [TBL] [Abstract][Full Text] [Related]
3. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR]. Luo Y; Li Y Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691 [TBL] [Abstract][Full Text] [Related]
4. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance. Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577 [TBL] [Abstract][Full Text] [Related]
5. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474 [TBL] [Abstract][Full Text] [Related]
6. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients. Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856 [TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850 [TBL] [Abstract][Full Text] [Related]
8. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer. Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762 [TBL] [Abstract][Full Text] [Related]
9. Detection of Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617 [TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011 [TBL] [Abstract][Full Text] [Related]
11. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974 [TBL] [Abstract][Full Text] [Related]
12. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093 [TBL] [Abstract][Full Text] [Related]
13. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Crucitta S; Ruglioni M; Novi C; Manganiello M; Arici R; Petrini I; Pardini E; Cucchiara F; Marmorino F; Cremolini C; Fogli S; Danesi R; Del Re M Clin Chim Acta; 2023 Feb; 541():117239. PubMed ID: 36736684 [TBL] [Abstract][Full Text] [Related]
14. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932 [TBL] [Abstract][Full Text] [Related]
16. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027 [TBL] [Abstract][Full Text] [Related]
17. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid. Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598 [TBL] [Abstract][Full Text] [Related]
18. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000 [TBL] [Abstract][Full Text] [Related]
20. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]